Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIS-NVAF trial
jRCTs051180202Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of warfarin, dabigatran, rivaroxaban, apixaban, edoxaban and 5 more in ischemic stroke, transient ischaemic attack (TIA), Atrial fibrillation (AFib) and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary composite endpoint. Started May 2017; status: completed.
02
Drugs
warfarindabigatranrivaroxabanapixabanedoxaban
03
Conditions
ischemic stroketransient ischaemic attack (TIA)Atrial fibrillation (AFib)atherosclerotic disease
Beyond the preview
Go deeper on jRCTs051180202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180202.